Tfeb Activators In Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
TFEB (Transcription Factor EB) is a master regulator of lysosomal biogenesis and autophagy. TFEB activators represent a promising therapeutic strategy for neurodegenerative diseases by enhancing the cell's ability to clear toxic protein aggregates. [1]
TFEB (Transcription Factor EB) is a master regulator of lysosomal biogenesis and autophagy. It controls the expression of genes involved in the lysosomal-autophagic pathway, making it a promising therapeutic target for neurodegenerative diseases characterized by protein aggregate accumulation. [2]
TFEB activators aim to enhance cellular clearance mechanisms by upregulating the Transcription Factor EB (TFEB) pathway, promoting lysosomal fusion with autophagosomes and improving the degradation of toxic protein aggregates in Alzheimer's Disease, Parkinson's Disease, and related disorders. [3]
TFEB is a basic helix-loop-helix leucine zipper transcription factor that coordinates the expression of genes involved in: [4]
| Compound | Mechanism | Development Stage | Reference | [5]
|----------|-----------|------------------|-----------|
| Trehalose | mTOR-independent TFEB activation | Preclinical/Phase I | [1] |
| Rapamycin | mTORC1 inhibition | Approved for other uses | [2] |
| Torin 1 | mTORC1/2 inhibition | Preclinical | [3] |
| Verapamil | mTOR inhibition | Approved for other uses | [4] |
| Gemfibrozil | PPAR-α agonist → TFEB | Preclinical | [5] |
| Amiodarone | mTOR inhibition | Approved for other uses | [6] |
| Arimoclomol | HSP90 co-inducer → TFEB/TFE3 activation | Phase II/III (NPC, ALS) | [7] |
| TPC2 Modulators (e.g., Chlorpromazine, Clomipramine) | Calcium-mediated TFEB activation via TPC2 | Preclinical | [8] |
TFEB activators may synergize with:
Arimoclomol is a heat-shock protein co-inducer that promotes TFEB and TFE3 nuclear translocation through a novel mechanism distinct from direct mTOR inhibition. [[7]]
Mechanism of Action:
Therapeutic Potential:
TPC2 is an endolysosomal calcium channel that regulates TFEB nuclear translocation through calcium-dependent signaling pathways. [[8]]
Mechanism of Action:
Therapeutic Potential:
Key References:
[6] Sarkar S, et al. "Trehalose enhances autophagy induction and protects cells from proteotoxic stress." Autophagy. 2007;3(5):478-479.
[1:1] Ravikumar B, et al. "Rapamycin treatment benefits neuronal function and survival in models of Huntington's disease and Alzheimer's disease." Human Molecular Genetics. 2010;19(14):2823-2838.
[2:1] Zhou J, et al. "TFEB activation promotes autophagy and clearance of toxic protein aggregates in neurodegenerative diseases." Molecular Neurobiology. 2021;58(5):2345-2361.
[3:1] Lu H, et al. "Verapamil induces autophagy and alleviates proteotoxicity in cellular models of Parkinson's disease." Neurobiology of Disease. 2019;132:104534.
[4:1] Ghosh S, et al. "TFEB activation by gemfibrozil, a PPAR-α agonist, ameliorates lysosomal dysfunction in Alzheimer's disease." Journal of Alzheimer's Disease. 2020;76(3):905-921.
[5:1] Zhang X, et al. "Amiodarone enhances TFEB-mediated autophagy and attenuates α-synuclein toxicity." Cell Death & Disease. 2021;12(11):1048.
The study of Tfeb Activators In Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Ravikumar B, et al. Rapamycin treatment benefits neuronal function and survival in models of Huntington's disease and Alzheimer's disease. Human Molecular Genetics. 2010. ↩︎ ↩︎
Zhou J, et al. TFEB activation promotes autophagy and clearance of toxic protein aggregates in neurodegenerative diseases. Molecular Neurobiology. 2021. ↩︎ ↩︎
Lu H, et al. Verapamil induces autophagy and alleviates proteotoxicity in cellular models of Parkinson's disease. Neurobiology of Disease. 2019. ↩︎ ↩︎
Ghosh S, et al. TFEB activation by gemfibrozil, a PPAR-α agonist, ameliorates lysosomal dysfunction in Alzheimer's disease. Journal of Alzheimer's Disease. 2020. ↩︎ ↩︎
Zhang X, et al. Amiodarone enhances TFEB-mediated autophagy and attenuates α-synuclein toxicity. Cell Death & Disease. 2021. ↩︎ ↩︎
Sarkar S, et al. Trehalose enhances autophagy induction and protects cells from proteotoxic stress. Autophagy. 2007. ↩︎